

# A study of the effect of BIIB122/DNL151 on midazolam in healthy participants

<b>Submission date</b> 01/04/2024	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 15/04/2024	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 09/05/2024	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

This is a drug-drug interaction (DDI) study to investigate the effect of BIIB122/DNL151 on the pharmacokinetics (PK) of oral MDZ and the safety and tolerability of BIIB122/DNL151 when administered alone and along with a single dose of MDZ. A DDI study is conducted to see how the two drugs interact in the body; evaluating PK is figuring out how participants' bodies handle a drug or drugs in combination.

### Who can participate?

Healthy volunteers aged 18 - 50 years old

### What does the study involve?

The total duration of each participant's involvement in the study will be approximately 7 weeks. At Visit 1, potential participants will be screened; at Visit 2, participants will be confined in a clinical research unit for 13 days; at Visit 3, participants will have an outpatient visit at the clinical research unit.

### What are the possible benefits and risks of participating?

Healthy volunteers will not receive any health benefit from participating in the study. The risks of participation are primarily those associated with adverse reactions to the study treatments and procedures; the risks of DNL151 treatment are based on extensive evaluation of nonclinical studies (ie, animal studies and studies done with cells in a petri dish) and evaluation in clinical studies in healthy participants to characterize the safety profile of BIIB122/DNL151.

### Where is the study run from?

Denali Therapeutics (USA)

### When is the study starting and how long is it expected to run for?

July 2021 to November 2021

### Who is funding the study?

Denali Therapeutics (USA)

Who is the main contact?

Clinical Trials Disclosures Group at Denali Therapeutics, [clinical-trials-disclosures@dnli.com](mailto:clinical-trials-disclosures@dnli.com)

## Contact information

### Type(s)

Principal investigator

### Contact name

Dr Helen Philpott

### Contact details

Simbec-Orion Clinical Pharmacology  
Merthyr Tydfil Industrial Park  
Cardiff Road  
Merthyr Tydfil  
United Kingdom  
CF48 4DR  
+44 (0)1443694315  
[helen.philpott@simbecorion.com](mailto:helen.philpott@simbecorion.com)

### Type(s)

Public, Scientific

### Contact name

Ms Gabrielle Brill

### Contact details

Simbec-Orion Clinical Pharmacology  
Merthyr Tydfil Industrial Park  
Cardiff Road  
Merthyr Tydfil  
United Kingdom  
CF48 4DR  
+44 (0)1443 694319  
[gabrielle.brill@simbecorion.com](mailto:gabrielle.brill@simbecorion.com)

### Type(s)

Public

### Contact name

Dr Clinical Trials Disclosures Group -

### Contact details

Denali Therapeutics  
-  
United States of America  
-  
None provided  
[clinical-trials-disclosures@dnli.com](mailto:clinical-trials-disclosures@dnli.com)

# Additional identifiers

## Clinical Trials Information System (CTIS)

2021-002708-10

## Integrated Research Application System (IRAS)

303787

## ClinicalTrials.gov (NCT)

Nil known

## Protocol serial number

DNLI-C-0008

# Study information

## Scientific Title

A drug-dr interaction study of the effect of BIIB122/DNL151 on midazolam pharmacokinetics in healthy participants

## Study objectives

To assess the pharmacokinetics (PK) of midazolam (MDZ) in the presence and absence of BIIB122 /DNL151

## Ethics approval required

Ethics approval required

## Ethics approval(s)

approved 13/09/2021, Wales Research Ethics Committee 1 (Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; +44 (0) 2922941119; Wales.REC1@wales.nhs.uk), ref: 21/WA/0261

## Study design

A fixed sequence crossover drug-drug interaction study

## Primary study design

Interventional

## Study type(s)

Other

## Health condition(s) or problem(s) studied

Healthy volunteers

## Interventions

Treatment Period 1: Single oral dose of MDZ

Treatment Period 2: Once daily oral dose of BIIB122/DNL151 for 10 consecutive days, coadministered with a single dose of MDZ on the 10th day

The total duration of each participant's involvement in the study will be approximately 7 weeks. At Visit 1, potential participants will be screened; at Visit 2, participants will be confined in a clinical research unit for 13 days; at Visit 3, participants will have an outpatient visit at the clinical research unit.

## **Intervention Type**

Drug

## **Phase**

Phase I

## **Drug/device/biological/vaccine name(s)**

BIIB122/DNL151; midazolam (MDZ)

## **Primary outcome(s)**

BIIB122/DNL151 and MDZ PK parameters, as measured by laboratory analysis of plasma concentrations from blood samples, including, but not limited to, the following:

1. Maximum concentration (C<sub>max</sub>)
  2. Area under the concentration-time curve from time zero to infinity (AUC<sub>∞</sub>)
  3. Area under the concentration-time curve from time zero to time of last measurable concentration (AUC<sub>last</sub>)
  4. AUC during a dosage interval (tau) (AUC<sub>τ</sub>)
- [Timeframe: Multiple timepoints over 15 days]

## **Key secondary outcome(s)**

1. BIIB122/DNL151 and MDZ PK parameters, as measured by laboratory analysis of plasma concentrations from blood samples, including, but not limited to, the following:

- 1.1. Time to maximum concentration (t<sub>max</sub>)
  - 1.2. Terminal elimination half-life (t<sub>1/2</sub>)
- [Timeframe: Multiple timepoints over 15 days]

2. Safety assessment including:

- 2.1. Incidence of treatment-emergent adverse events (TEAEs) and SAEs as reported by the participant [Timeframe: Continuously over 15 days]
- 2.2. Laboratory assessments of blood and urine samples (including hematology, serum clinical chemistry, and urinalysis) [Timeframe: Multiple timepoints over 15 days]
- 2.3. 12-lead electrocardiograms (ECGs) [Timeframe: Multiple timepoints over 15 days]
- 2.4. Vital sign abnormalities [Timeframe: Multiple timepoints over 15 days]
- 2.5. Physical examinations [Timeframe: Multiple timepoints over 15 days]
- 2.6. Suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) [Timeframe: Multiple timepoints over 15 days]

## **Completion date**

19/11/2021

## **Eligibility**

### **Key inclusion criteria**

1. Healthy female participants of non-childbearing potential or healthy male participants between 18 and 50 years of age, inclusive
2. Body mass index (BMI) between 18.5 and 31.0 kg/m<sup>2</sup> and a body weight of at least 50 kg

**Participant type(s)**

Healthy volunteer

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

50 years

**Sex**

All

**Total final enrolment**

14

**Key exclusion criteria**

1. Take any concomitant medication at the time of screening or during the study, unless deemed acceptable by the investigator (or designee) and Sponsor
2. Any history of hepatic, pulmonary, and/or renal disease
3. History of serious adverse reaction or serious hypersensitivity to any drug
4. History of allergy to any component of the study intervention
5. Have any surgical or medical condition affecting drug absorption (eg, gastrectomy)

**Date of first enrolment**

27/09/2021

**Date of final enrolment**

04/11/2021

**Locations****Countries of recruitment**

United Kingdom

Wales

**Study participating centre**

**Simbec-Orion Clinical Pharmacology (AKA Simbec Research Ltd)**

Merthyr Tydfil Industrial Park

Cardiff Road

Merthyr Tydfil  
United Kingdom  
CF48 4DR

## Sponsor information

**Organisation**  
Denali Therapeutics Inc.

## Funder(s)

**Funder type**  
Industry

**Funder Name**  
Denali Therapeutics

**Alternative Name(s)**  
DENALI, Denali Therapeutics Inc.

**Funding Body Type**  
Government organisation

**Funding Body Subtype**  
For-profit companies (industry)

**Location**  
United States of America

## Results and Publications

**Individual participant data (IPD) sharing plan**  
The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

**IPD sharing plan summary**  
Not expected to be made available

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Basic results</a>		19/04/2024	22/04/2024	No	No

<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes
---	-------------------------------	------------	------------	----	-----